Wednesday’s Highlights at Noon: Biocept Inc (BIOC), Orexigen (OREX), ImmunoCellular Therapeutics (IMUC), Advaxis (ADXS), Curis Inc (CRIS)

By Carrie Williams

So far Wednesday, January 16, NASDAQ is down -0.16% and the S&P is up 0.28%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Biocept Inc (BIOCResearch Report), Orexigen (OREXResearch Report), ImmunoCellular Therapeutics (IMUCResearch Report), Advaxis (ADXSResearch Report) and Curis Inc (CRISResearch Report).

Biocept Inc is up 115.59% in midday trading to $3.56. Shares opened today at $1.65. The company has a 52-week low of $0.66 and a 52-week high of $0.00.

Orexigen is down -62% in midday trading to $0.00. Shares opened today at $0.01. The company has a 52-week low of $0.00 and a 52-week high of $0.00. Over the last 3 months, the insider sentiment on Orexigen has been negative based on 3 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

ImmunoCellular Therapeutics is up 40% in midday trading to $0.03. Shares opened today at $0.02. The company has a 52-week low of $0.01 and a 52-week high of $0.00.

See today’s analyst top recommended stocks >>

Advaxis is up 17.55% in midday trading to $0.36. Shares opened today at $0.30. The company has a 52-week low of $0.18 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $3.00, marking a 893.38% potential upside from current levels. In a report released today, H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Hold rating on ADXS. Separately, on December 17, Alliance Global Partners’ James Molloy maintained a Buy rating on the stock and has a price target of $3.

See today’s analyst top recommended stocks >>

Curis Inc is up 13.13% in midday trading to $1.12. Shares opened today at $0.99. The company has a 52-week low of $0.60 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $3.00, marking a 203.03% potential upside from current levels. In a report issued on November 1, Robert W. Baird analyst Brian Skorney maintained a Buy rating on CRIS, with a price target of $3, which represents a potential upside of 203% from where the stock is currently trading.

Trending Stocks Based on Insider Activity >>